Study Details
Adalimumab Drug Levels of People with Chronic Anterior Uveitis
(IRB#: IRB_00163045)
Chronic anterior uveitis (middle layer of the eye) disease is a condition that causes inflammation (swelling) of the eye. This can lead to pain, redness, and decreased vision. The study wants to see whether blood levels of adalimumab can be used to predict how well the uveitis will respond to adalimumab. People in the study will have already planned to start adalimumab for chronic anterior uveitis. Being in the study lasts 6 months and requires attending 3 visits to the study clinic during planned regular visits with ophthalmology (eye doctor) and sometimes rheumatology (doctor treating diseases that can affect the body's connective tissues, causing pain, swelling, and stiffness). Medical tests will be done to track the health of participants.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages less than 18 years
- Diagnosis of chronic anterior uveitis
- Active uveitis at the start of taking adalimumab
- Able to speak and read English
- Attend in-person visits at the study clinic
Exclusion Criteria
- Diagnosis of infectious (able to spread to others) uveitis
- Prior treatment with adalimumab for any condition
- History of cancer
- History of demyelinating disease (a condition that damages the protective covering of most nerves in the body)
- Systemic corticosteroid use (using steroid medication that affects the whole body) at the time of study participation
Will I be paid for my time?
No
IRB#: IRB_00163045
PI: John Bohnsack
Department: PEDIATRICS
Approval Date: 2023-12-13 07:00:00
Specialties: Rheumatology
I am Interested